Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Gyre Therapeutics Inc. maintains a portfolio in the Biotechnology & Pharmaceuticals technology area. There are 2 pending office actions currently associated with the company. These actions are split between 2 distinct examiners. This distribution suggests that the company's active applications are being treated as separate technical efforts.
The workload is further divided across 2 distinct art units. SAMSELL, RILLA MARIE is the busiest examiner, with 1 pending office action. This distribution shows that the 2 pending actions are being processed independently by different examiners in 2 different art units. For a practitioner, this means that the prosecution strategy must be tailored to 2 different sets of examiner expectations and 2 different art unit environments. The lack of overlap between 2 examiners and 2 art units for these 2 pending actions indicates a range of subject matter within the active portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SAMSELL, RILLA MARIE | 1 | 70.8% | +4.6% |
| SZNAIDMAN, MARCOS L | 1 | 37.3% | +16.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18381550 | PHARMACEUTICAL HYDRONIDONE FORMULATIONS FOR DISEASES | SZNAIDMAN, MARCOS L | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18560696 | APPLICATION OF HYDRONIDONE IN PREPARATION OF DRUG FOR TREATING OR PREVENTING CHRONIC HEPATITIS B WITH LIVER FIBROSIS | SAMSELL, RILLA MARIE | 1624 | §103 | Final Rejection | 12d | Pending | Dec 15, 2023 |
| 18381550 | PHARMACEUTICAL HYDRONIDONE FORMULATIONS FOR DISEASES | SZNAIDMAN, MARCOS L | 1628 | §103 | Non-Final OA | — | Pending | Oct 18, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial